Skip to content

Research of CGM for Evaluating Dawn Phenomenon in Type 2 Diabetes Patients

Real-world Retrospective Study on Continuous Glucose Monitoring in the Evaluation of Dawn Phenomenon in Patients with Type 2 Diabetes Mellitus

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126905
Enrollment
Unknown
Registered
2026-06-18
Start date
2026-06-22
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus and Diabetic Dawn Phenomenon

Interventions

Type 2 diabetes patients with dawn phenomenon&Type 2 diabetes patients without dawn phenomenon:None

Sponsors

The First Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged over 18 years, no restriction on gender; 2.Inclusion criteria for diabetes: The diagnosis of type 2 diabetes mellitus conforms to the World Health Organization (1999) diagnostic criteria; 3.Wearing Abbott FreeStyle Libre continuous glucose monitor; the CGM monitoring duration is no less than 72 hours, and the valid coverage data rate is no less than 80% (blood glucose values excluding invalid records such as signal interference); 4.During CGM wearing period, capillary blood glucose calibration was performed at least four times per day; 5.With a stable therapeutic regimen for diabetes; 6.Complete clinical data were available (including demographic characteristics, biochemical indicators, medication history, etc.).

Exclusion criteria

Exclusion criteria: 1.Non-type 2 diabetes mellitus, including type 1 diabetes mellitus, gestational diabetes mellitus, pancreatogenic diabetes, monogenic diabetes, or cystic fibrosis-related diabetes; 2.Incomplete CGM data or data with obvious quality defects; 3.Patients with severe and recurrent hypoglycemia indicated by CGM data; 4.Patients with mental disorders who are unable to cooperate with data collection; 5.Incomplete clinical data that cannot meet the requirements for research analysis.

Design outcomes

Primary

MeasureTime frame
Prevalence of dawn phenomenon;

Secondary

MeasureTime frame
Core characteristic indicators of the dawn phenomenon;Overall glycemic control and glucose variability parameters;

Countries

China

Contacts

Public ContactLong Min

The First Affiliated Hospital of Army Medical University

Longmin_casper@163.com+86 23 68765441

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 29, 2026